| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX009 (ip) | median survival time | saline | 1.5 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.5 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 15.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 15.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 25.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 50.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 50.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 100.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 100.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 150.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 150.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 150.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 200.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 200.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 300.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 300.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 300.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 400.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 400.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 600.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 600.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 600.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1200.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 50.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 100.0 mg/kg/injection | 83.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 200.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 400.0 mg/kg/injection | 83.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |